Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alpine will easily raise their share price by buying back shares with the influx of cash coming in from multiple sources. At the current P/S the entire float, which is far less than 50 million, could be purchased for less than $8 million. Once the PPS is in the dollars and the up-listing has been completed, Alpine could easily sell back a fraction of those shares in an offering to totally wipe out that debt, plus have the cash to fund their expansion.
Please, if you don't think ALPP is the ultimate OTC investment...
Tell us what in your opinion is better and why, or shut up.
I'm in, it's undeniable...
I've been following this company, and I like it a lot. In the absence of news, without an immediate catalyst, people will trade on both trends and more often than not, charts. And there's a big chart right above us. You can draw a perfect line from the closing PPS today down to .095 hitting all four points perfectly. The 50 day moving average is right below .12 and a support line at .095. I'm looking to go long too. Like I said, I like this company and the CEO. But there are a lot of people that have really cheap shares, and regardless of what is said here, there is a lot of profit taking going on, which so far, those who have are feeling good about their trading decisions. Everyone here, and I mean everyone, is here for one thing only. To make money, not to lose money.
This my third run at this, I'm all in, because there is no way this can go south a third time. These people aren't stupid. But all those who sold will feel stupid.
The great thing about a cheap lottery ticket is that you can leave it sit there forever without any worries, and I'm not worried.
This is why there is such a large shorter's consortium in the OTC markets. And when their is a solid opportunity, there are few investors with the nerve (BALLs) to ride it to fruition. It's funny, how easily they play these children. Me, I'm not worried, I have the patience, and that's why there's such huge easy money to be made here.
I'm in and I swear to God I ain't nervous... Wayne will tell you why!
It won't take much news to run this into the Dollars. We're heading into the Football betting season, which will generate constant news and constant new highs.
In at .75, this is a hot sector, people like to gamble on sports, it's legal, low float, it's a relatively new company, and it's a listed stock.
I JUST SPOKE TO DWIGHT BABCOCK
I told him about our concern about that article and the lack of a response,HE SAID THAT THE ATTORNEYS OF ISR ARE INVESTIGATING THE CASE,AND WHEN THEY ARE READY,THERE WILL BE A RESPONSE,i also asked him about the future earnings,he said he couldn't give me any answers in the matter,but he said THAT EVERYTHING IS MOVING ALONG AS PREDICTED,AND IN A MONTH WE SHOULD HAVE SOME ANSWERS IN ABOUT A MONTH,i also told him our concern about THE COMPANY BEING PUT OUT OF BUSINESS,AND HE SAID CLEARLY==NOT A CHANCE FOR THIS TO HAPPEN==HIS WORDS AND NOT MINE,that's when he said things should clear up in a month,for now he said,he is just doing business as usual and is letting his lawyers doing their job without interfering,that's all folks. (Posted By yborcat2 on yahoo)
(And here is a follow-up response to further bashing): yyzsb,it's all true,i just spoke on the phone with one of the longs,and I told him exactly what happened,infact I'm in touch with one of the long investors,good things will come again,meanwhile I keep buying, good luck to all of us and remember,BABCOCK IS DOING HIS JOB,INFACT HE TOLD ME NOT TO WORRY ABOUT THE CURRENT SITUATION
FDA approved for treating brain cancer, prostate cancer, lung cancer, ocular cancer, head and neck cancer, and other cancers throughout the body. What is so incredible about Cesium-131 is that it has an unbelievably high success rate and minimal side effects compared to other cancer treatments.
I couldn't have said it any better PB, there's Gold in those seeds!
What a gift to have gotten in today. Ridiculously low, a ton of money, and still a low O/S structure. Down side risk is virtually nil at $2, and with a $17.7MM grant and around $25MM more coming in next week, they're swimming in cash. This has multi-bagger written all over it, and within weeks, not years.
I have seen enough videos and read enough articles to know that we have an incredible life-saving, FDA approve product, with a fine CEO. For me, anything contrary or personal is obviously short-motivated, period, end of story. There are no ISR issues, we will see PPS north of $10 soon enough, all the BS in the world can't stop the avalanche of life saving news that continues to come.
You're right great article and JohnnyCashingIn, please stick it right on top!
I have yet to see any legitimate source that agrees with Adam Feuerstein. The downside risk is almost non existent and the upside is astronomical. It's funny how easily people are manipulated and spooked.
OMG, This Person just created this account for the expressed purpose of posting this wisdom. He knows what he's talking about, and though he made a few grammatical errors, probably on purpose, he is connected! To a savvy investor this should not have been a revelation. The FDA approved Cesium-131 because it is a much more effective treatment. The point of contention is how fast will they make money. Think about it. We live in an age where information spreads in an instant. If you had cancer and you knew about Cesium-131, liquid or seeds, wouldn't you demand it. I don't care if there is another treatment that's almost as effective, that destroys your immune system. If I have cancer, almost isn't good enough. This is blatantly the easiest multi-bagger you will ever see! Thank you "the_profit29", an educated man, probably an insider, but in any case, a defender of the truth. I pray that this isn't your only post! You have one post and one follower. And I venture to say, that you will have more followers than posts.
If you or me had a Tumor what would we do? Of course, we would have it removed and of course we would have those seed put right there in case the tumor came back. Nobody in their right mind would do anything less. ISR has a lock on the future. Cry wolf all you want, we are immune from the scam and ambulance chasing nonsense.
As much as I like this company, they will not get into a street fight and without substantiation we're going back down.
There's no downside here, the company is well financed with only a little over 50MM shares outstanding.
We'll easily hit $10. Cesium-131 seeds, the next best thing to a cancer cure. If it does this well against the very difficult lung cancer, just think how effective it will be against many other types of cancer. Seriously, the sky is the limit, major upside coming. The news and articles and TV coverage will be endless.
Why would anyone sell this? We now have Profitability and the news will never stop coming! There is no telling how high this will go. Definitely double figures!
Analyst Jason Kolbert noted, “Isoray has received more physician and medical center inquires about Cs-131 in April 2015 alone than in the previous 2 years. We believe this bodes very well for the forward outlook to gain traction for Cs-131 adoption. Physician adoption is key to Cs-131 and Isoray's success. Isoray, through multiple publications, and abstract presentations at major conferences, is driving awareness to plant the seeds (no pun intended) for Cs-131 adoption.”
Overall: “We believe Cs-131 is a more efficacious, safer alternative to SOC isotopes Iodine-125 or Palladium-103. Cs-131 hits the tumor faster and harder (shorter half life) which should convince physicians to adopt. As Cs-131 is now in centers in the east, west and central parts of the US, we believe adoption will continue. More data and more publications are coming to help the push.”
Not even close, dream on with that sub-penny nonsense.
I'll tell you what the reality is. No one seems to be moved to sell. Fear tactics have had no effect. It seems to me that people here understand the fact that this company has continued to work this promising technology with very little dilution and that's the type of commitment most of us are looking for in a start up penny technology. The downside for most of us is a small investment, even with the past reverse split. But the upside, if this technology becomes commercialized, we will see at least a 20 bagger and probably closer to a 100 bagger. Talk about a serious risk / reward ratio. That's a lottery ticket that most of us are not willing to cash in prematurely.
Not True, yes someone has to sell if there is to be a buy. But if almost all of the transactions are at the ask, especially with this big spread, then they are mostly all BUYS!
Almost every share has been transacted at the ASK. A lot of people are now in the black, but very few are selling.
MMTC has been trading two or three thousand shares a day for years, and now so far today we have traded One Hundred Forty Three Thousand, AT Fifteen Cents, up almost 100%! This is not retail. The majority of this volume has to be privileged insider information leakage!
Yes, no doubt, I endured the reverse split too. But I believed then and I believe now, and when you believe you have to move forward, buy some more, lower your cost average, and be patient. The shares are cheep cotton. Buy a few, hedge your opinion in case you're wrong. It's possible, seriously, I'm just trying to be helpful.
Say what you want. The fact is obvious. Almost No one is selling. The shares are locked. We that remain will see this to the end. Regardless of the consequence - reward scenario. To the beginning!
You can't argue with success and facts. We will see many multiples from here. Patience! I've endured a reverse split and still believed, and averaged down. I'm following the money. If China dumps millions into CLSN, which is what happened, then who am I to argue. Money in the Bank!
According to CRT Capital, Adamis, with their recently raised $10.6 Million Cash, Adamis has sufficient cash to launch its epinephrine pre-filled syringe (for the treatment of anaphylaxis) and continue to develop its respiratory treatment pipeline, which includes APC-5000, APC-1000 (HFA beclomethasone comparable to Teva's QVAR), and APC-3000. IN MY OPINION, we are just about to embark on a period of indestructibility, with a continuation and acceleration to $70. Adamis has the cash to develop its products in a market worth 10's of billions of dollars. With a market cap of less than 100M, this is an easy 10 bagger, $70 PPS, and that doesn't even get us to a respectable 1B market cap.
ADMP $6.50 - FDA decision due by the end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015- - 10% market share is about $100 Million in sales. X 20% profit margin = $20 Million profit DIVIDED by 15 million shares outstanding = $1.33 EPS X conservative 30 PE = $40 PPS. ALSO - low risk, quicker path to revenues for a robust generic pipeline, including the APC-5000 generic Advair, that address markets totaling over $13 billion. Major Multi-Bagger here!
ADMP $6.50 - FDA decision due by the end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015- - 10% market share is about $100 Million in sales. X 20% profit margin = $20 Million profit DIVIDED by 15 million shares outstanding = $1.33 EPS X conservative 30 PE = $40 PPS. ALSO - low risk, quicker path to revenues for a robust generic pipeline, including the APC-5000 generic Advair, that address markets totaling over $13 billion. Major Multi-Bagger here!
ADMP $6.50 - FDA decision due by the end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015- - 10% market share is about $100 Million in sales. X 20% profit margin = $20 Million profit DIVIDED by 15 million shares outstanding = $1.33 EPS X conservative 30 PE = $40 PPS. ALSO - low risk, quicker path to revenues for a robust generic pipeline, including the APC-5000 generic Advair, that address markets totaling over $13 billion. Major Multi-Bagger here!
ADMP $6.50 - FDA decision due by the end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015- - 10% market share is about $100 Million in sales. X 20% profit margin = $20 Million profit DIVIDED by 15 million shares outstanding = $1.33 EPS X conservative 30 PE = $40 PPS. ALSO - low risk, quicker path to revenues for a robust generic pipeline, including the APC-5000 generic Advair, that address markets totaling over $13 billion. Major Multi-Bagger here!
ADMP $6.50 - FDA decision due by the end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015- - 10% market share is about $100 Million in sales. X 20% profit margin = $20 Million profit DIVIDED by 15 million shares outstanding = $1.33 EPS X conservative 30 PE = $40 PPS. ALSO - low risk, quicker path to revenues for a robust generic pipeline, including the APC-5000 generic Advair, that address markets totaling over $13 billion. Major Multi-Bagger here!
ADMP $6.50 - FDA decision due by the end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015- - 10% market share is about $100 Million in sales. X 20% profit margin = $20 Million profit DIVIDED by 15 million shares outstanding = $1.33 EPS X conservative 30 PE = $40 PPS. ALSO - low risk, quicker path to revenues for a robust generic pipeline, including the APC-5000 generic Advair, that address markets totaling over $13 billion. Major Multi-Bagger here!
ADMP $6.50 - FDA decision due by the end of March for their Epinephrine (EPI) Pre-Filled Syringe (PFS) with revenues expected 1H 2015- - 10% market share is about $100 Million in sales. X 20% profit margin = $20 Million profit DIVIDED by 15 million shares outstanding = $1.33 EPS X conservative 30 PE = $40 PPS. ALSO - low risk, quicker path to revenues for a robust generic pipeline, including the APC-5000 generic Advair, that address markets totaling over $13 billion. Major Multi-Bagger here!